Angiochem raises $7.5 mln to develop breast cancer compound
Angiochem Inc, a Montréal-based clinical-stage biotechnology company, has secured $7.5 million in a Series C financing. The round's investors were not disclosed. Angiochem has previously raised financing from BDC Capital's Healthcare Venture Fund, the life sciences group of Vimac Ventures, and other sources. Angiochem said the funds raised will be used to support development of ANG1005. The compound is intended to treat leptomeningeal carcinomatosis from breast cancer, for which there are no therapeutic options at present. Founded in 2003, Angiochem is developing a product pipeline for the treatment of a range of central nervous system diseases.
1 August 2018•2 mins read
